Decitabine, a DNMTi, has been shown to induce the expression of chondroitin sulfate proteoglycan 4 (CSPG4) on ovarian cancer cells, such as SKOV-3, in a dose-dependent manner. This evidence concerns the gene CSPG4 and ovarian carcinoma.